Understanding m6A changes in chromophobe renal cell carcinoma and predicting patient outcomes survival

N6-methyladenosine (m A) is a prevalent mRNA modification known for its implications in various cancer types, yet its role in chromophobe renal cell carcinoma (chRCC) remains largely unexplored. In this study, we performed m6A-SEAL-seq and RNA-seq analyses on tissues from three chRCC subjects, aiming to uncover m A alterations in chRCC. Our findings revealed reduced expression levels of four m A regulators in chRCC tissues and highlighted differences in m A levels compared to normal tissues. Furthermore, we identified specific genes and cancer-related pathways affected by these differences, including notable candidates like NOTCH1 and FGFR1, implicated in chRCC development. Additionally, we developed a predictive model based on the expression level of m A associated genes, demonstrating promising prognostic capabilities for patient survival prediction. Overall, our study provides valuable insights into the role of m A in chRCC and its potential as a prognostic indicator.